Copyright 1995-2026 Takeda Pharmaceutical Company Limited. All rights reserved.
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026 ...
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 24, 2025 – Takeda (TSE:4502/NYSE:TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility ...
OSAKA, Japan, May 9, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024). Takeda delivered its Management Guidance for Core Operating ...
OSAKA, Japan and CAMBRIDGE, Massachusetts, October 1, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced that as part of a strategic portfolio prioritization process, the company has made the decision ...
Brings together complementary positions in gastroenterology (GI) and neuroscience; provides leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and ...
GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...
Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks 1 At the Highest Dose of ...
OSAKA, Japan and CAMBRIDGE, Massachusetts, July 11, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced that the Company has voluntarily withdrawn the U.S. Biologics License Application (BLA) for its ...
OSAKA, Japan and CAMBRIDGE, Massachusetts, January 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced the decision to discontinue its soticlestat (TAK-935) development program. In the quarter that ...
Osaka, JAPAN, September 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today reaffirmed its commitment to expand its manufacturing capacity for plasma-derived therapies (PDTs) in Juso, Osaka, and provided an ...
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 25, 2025 – Takeda (TSE:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results